Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07408258 · ClinicalTrials.gov registry record · Phase 1

Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors

A Phase 1 study, sponsored by OncoC4.

Not yet
Registry status
Phase 1
Development phase
20
Enrollment target

NCT07408258 is a Phase 1 study that has not yet begun recruiting, run by OncoC4. The registered enrollment target is 20 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07408258, a Phase 1 study, has not yet begun recruiting, sponsored by OncoC4.

NOT YET RECRUITING
Registry status
Phase 1
Development phase
20 participants
Enrollment target

Study Summary

ONC-783-001 is a Phase I open label, dose-escalation study for evaluating the safety, pharmacokinetics (PK) and efficacy of ONC-783 as a single agent in patients with advanced/metastatic solid tumors, focusing on colorectal cancer, ovarian cancer, pancreatic cancer, or breast cancer.

Interventions

  • DRUG ONC-783

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2026-06-01
Est. Completion 2028-06-01
Phase Phase 1

Sponsor

OncoC4

7 total trials

What the Registry Record Tells You About NCT07408258

The ClinicalTrials.gov registry entry for NCT07408258 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OncoC4, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which ONC-783 is the first listed.

NCT07408258 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT07408258 about?

NCT07408258 is a clinical study titled "Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors". ONC-783-001 is a Phase I open label, dose-escalation study for evaluating the safety, pharmacokinetics (PK) and efficacy of ONC-783 as a single agent in patients with advanced/metastatic solid tumors, focusing on colorectal cancer, ovarian cancer, pancreatic cancer, or breast cancer.

What is the current status of trial NCT07408258?

This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2026-06-01. Estimated completion is 2028-06-01.

What interventions are being tested in trial NCT07408258?

The interventions under investigation include: ONC-783 (DRUG).

Who is sponsoring clinical trial NCT07408258?

This trial is sponsored by OncoC4, which has 7 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.